FocalTherics Q3 Earnings Call Highlights
FocalTherics reported Q3 earnings, highlighting sales to new hospitals and 32% YoY procedure growth. Revenue rose 24%, gross margin improved to 51.4%, and net loss narrowed to $4.5M. Cash increased to $56.3M post-equity offering. The company expects consistent procedure growth in 2027, with new coverage policies and clinical studies underway.


